Sandoz H2 Launch Ramp-Up Begins With A US First
Novartis Subsidiary Launches High Dose Intravenous Iron, Ferumoxytol Injection
Sandoz has kicked off what promises to be a busy second half of 2021 in terms of launches for the Novartis subsidiary, introducing the first US generic of the Feraheme feumoxytol injectable treatment for iron deficiency anemia.
You may also be interested in...
Sandoz saw both its sales and core operating profit experience double-digit drops in what management described as a “challenging” first quarter of 2021. However, its performance is expected to stabilize in the back end of the year as pandemic-related pressures ease.
Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.